NASDAQ:SABS SAB Biotherapeutics (SABS) Stock Price, News & Analysis $3.39 -0.11 (-3.14%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$3.37 -0.02 (-0.62%) As of 09/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About SAB Biotherapeutics Stock (NASDAQ:SABS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SAB Biotherapeutics alerts:Sign Up Key Stats Today's Range$3.31▼$3.5550-Day Range$3.39▼$3.9352-Week Range$1.85▼$5.15Volume406,673 shsAverage Volume379,421 shsMarket Capitalization$308.46 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing targeted antibody-based medicines for infectious diseases and immune-mediated conditions. The company’s approach is designed to produce fully human polyclonal antibodies that can recognize and neutralize multiple targets associated with a disease. SAB’s technology platform, known as DiversitAb, uses genetically engineered cattle that are capable of producing human antibodies. Antibodies harvested from the animals’ plasma are evaluated for potential use as therapeutics. The company has applied this platform to programs addressing viral infections, including COVID-19 and influenza, as well as autoimmune and other immune-related diseases. One of SAB’s best-known development programs is SAB-185, an investigational fully human polyclonal antibody therapy developed for COVID-19. The company has also advanced antibody programs such as SAB-176 for influenza and SAB-142 for immune-mediated conditions. Its activities are primarily focused on research, clinical development and regulatory advancement in the United States. SAB Biotherapeutics is headquartered in Sioux Falls, South Dakota. The company was founded by Eddie J. Sullivan, who has served as its chief executive officer and has been involved in developing its antibody-production platform. SAB Biotherapeutics became a publicly traded company on Nasdaq in 2021.AI Generated. May Contain Errors. Read More SAB Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreSABS MarketRank™: SAB Biotherapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 592nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingSAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSAB Biotherapeutics has a consensus price target of $12.00, representing about 254.0% upside from its current price of $3.39.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about SAB Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SAB Biotherapeutics are expected to grow in the coming year, from ($1.17) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SAB Biotherapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SAB Biotherapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about SAB Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.89% of the float of SAB Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSAB Biotherapeutics has a short interest ratio ("days to cover") of 12.62, which indicates bearish sentiment.Change versus previous monthShort interest in SAB Biotherapeutics has recently decreased by 10.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for SAB Biotherapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for SABS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.39% of the stock of SAB Biotherapeutics is held by insiders.Percentage Held by Institutions7.82% of the stock of SAB Biotherapeutics is held by institutions.Read more about SAB Biotherapeutics' insider trading history. Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SABS Stock News HeadlinesSAB Biotherapeutics, Inc. Announces Presentations Of SAB-142 Data At The 62nd Annual Meeting Of The European Association For The Study Of DiabetesSeptember 22 at 3:11 PM | marketscreener.comMSAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of DiabetesSeptember 22 at 8:30 AM | globenewswire.comBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-largest miner running on fumes. Newmont's $15 billion purchase of Newcrest, the largest mining deal in history, still couldn't keep output growing, proof that majors must keep buying to survive. With record cash flows and shrinking mines, gold majors are positioned to launch a wave of acquisitions targeting the best junior assets. | Golden Portfolio (Ad)SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 10, 2026 | seekingalpha.comSAB BIO to Participate in Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)August 8, 2026 | theglobeandmail.comSAB BIO Reports Q2 2026 Financial Results and Provides Business HighlightsAugust 6, 2026 | globenewswire.comSAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 AssessmentJuly 15, 2026 | finance.yahoo.comSee More Headlines SABS Stock Analysis - Frequently Asked Questions How have SABS shares performed this year? SAB Biotherapeutics' stock was trading at $3.74 on January 1st, 2026. Since then, SABS shares have decreased by 9.4% and is now trading at $3.39. How were SAB Biotherapeutics' earnings last quarter? SAB Biotherapeutics, Inc. (NASDAQ:SABS) announced its earnings results on Thursday, August, 6th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.00. Read the conference call transcript. Who are SAB Biotherapeutics' major shareholders? Top institutional shareholders of SAB Biotherapeutics include Seven Fleet Capital Management LP (0.81%), AWM Investment Company Inc. (0.41%), Bank of New York Mellon Corp (0.14%) and IFP Advisors Inc (0.04%). Insiders that own company stock include Eddie Joe Sullivan and Michael King. View institutional ownership trends. How do I buy shares of SAB Biotherapeutics? Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SAB Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that SAB Biotherapeutics investors own include ChargePoint (CHPT), PayPal (PYPL), Coinbase Global (COIN), Tesla (TSLA), Confluent (CFLT), CrowdStrike (CRWD) and Ford Motor (F). Company Calendar Last Earnings8/06/2026Today9/23/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SABS's financial health is in the Green zone, according to TradeSmith. SABS has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SABS CIK1833214 Webwww.sab.bio Phone(305) 845-2813FaxN/AEmployees86Year Founded2014Price Target and Rating Average Price Target for SAB Biotherapeutics$12.00 High Price Target$16.00 Low Price Target$7.00 Potential Upside/Downside+254.0%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$13.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-6.74% Return on Assets-6.06% Debt Debt-to-Equity Ratio0.01 Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$1.32 million Price / Sales233.68 Cash Flow$0.33 per share Price / Cash Flow10.24 Book Value$3.18 per share Price / Book1.07Miscellaneous Outstanding Shares90,990,000Free Float84,262,000Market Cap$308.46 million OptionableNot Optionable Beta0.53 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:SABS) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredThe REAL Reason 2,000 Missiles Rained on IranTwo private meetings with U.S. Congressmen and weeks of research point to a surprising explanation for the rec...Behind the Markets | SponsoredAmazon's touch-enabled robot points to AI's next phaseAmazon wants touch-enabled robots to handle 80% of work across roughly 14 billion warehouse items a year. One ...The Oxford Club | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
